To assess the safety and efficacy of aneurysm embolization performed using Guglielmi detachable coils (GDCs), the authors reviewed the results of a cohort of 150 patients with either ruptured (83 patients) or unruptured (67 patients) basilar tip aneurysms treated with these detachable platinum coil devices in the early part of the United States multicenter GDC clinical trial that led to Food and Drug Administration approval for the device.
clipping for a variety of reasons. [31] In an effort to improve outcome, endovascular embolization of aneurysms performed using Guglielmi detachable coils (GDCs) (Target Therapeutics, Fremont, CA) is currently being evaluated as a viable treatment option and as an adjunct to the proven definitive treatment of surgical clipping in selected instances in which clipping is not feasible or desired. [4, [6] [7] [8] 18, 27] Patients in poor medical or neurological condition and those who have aneurysms that are inaccessible may benefit from this relatively immature, unproven but promising, endovascular procedure because it may at least provide protection from early rebleeding during the acute period. [5] Microsurgical access to basilar tip aneurysms is often challenging; although strides have been made in their treatment, it remains technically more difficult to obliterate these aneurysms surgically, especially if they are giant, and patients who have these aneurysms exhibit significantly worse results than those who have been surgically treated for nonbasilar tip aneurysms. [2, 10, 28] For a subset of patients with basilar tip aneurysms, endovascular GDC embolization may prove particularly effective in improving clinical outcome.
Under an investigational device exemption approved by the United States Food and Drug Administration (FDA), a multicenter investigational study was conducted in the United States to evaluate the safety and efficacy of GDCs in the treatment of ruptured and unruptured intracranial aneurysms in patients who are deemed to be at high risk for surgery. We present the results of the cohort of 150 patients with basilar tip aneurysms treated with the GDC system during the early period of the FDA multicenter clinical trial. [1] 
CLINICAL MATERIAL AND METHODS

Patient Population
From January 1991 to September 1995, 159 patients who harbored basilar tip aneurysms were enrolled for endovascular therapy to be performed with detachable platinum coils at 21 centers throughout the United States (Appendix). In general, only those individuals judged to be in such a grave clinical condition that intervention would be of no possible benefit or those who had other medical, social, or psychological problems that rendered them ineligible for experimental protocols were excluded from entry into the study. (Exceptions to these criteria were six patients with Hunt and Hess [11] Grade V aneurysms who were in grave clinical condition but nevertheless were treated.) Patients were selected for endovascular therapy after the referring neurosurgeon excluded the patient as a surgical candidate. Reasons for exclusion from surgery included anticipated surgical or technical problem (111 patients), previous failure of surgical therapy (28 patients), myocardial infarction (two patients), previous failure of nonsurgical treatment (one patient), patient refusal (one patient), and other nonspecified reasons (16 patients). One hundred fifty of these patients were treated with the GDC system.
Of the 150 treated patients, there were 101 women and 48 men (information on gender was missing in one patient) and these patients ranged in age from 27.9 to 85.7 years with a mean of 51.9 years. Eighty-three patients had ruptured and 67 had unruptured basilar tip aneurysms. In the patients with ruptured aneurysms, 23 (28%) were assigned Hunt and Hess Grade I; 20 (24%) Grade II; 22 (27%) Grade III; 10 (12%) Grade IV; six (7%) Grade V; and in two (2%) grade data were missing. Of the 67 patients who had unruptured basilar tip aneurysms, only nine were asymptomatic; 49 had symptomatic aneurysms measuring 25 mm or less and nine had symptomatic giant aneurysms (> 25 mm). The angiographically measured sizes of the treated basilar tip aneurysms are listed in Table 1 . No accurate assessment of aneurysm neck size was made. Of the 83 patients with ruptured aneurysms, 56 were treated within 2 weeks of the initial subarachnoid hemorrhage; the remaining 27 patients were treated after 2 weeks.
Assessment of Aneurysm Embolization
In some circumstances, staged treatment was deliberate: this approach provided the safest means to pack the base of the aneurysm satisfactorily with coils. This was particularly true in cases of unruptured aneurysms, which have a low 2 to 3% per year [14, 31] risk of rupture. The percentage of occlusion was evaluated as a means for determining technical success and not as a predictor of clinical success. Percentage of occlusion and adverse events were assessed by the treating endovascular interventionalist. The percentage of occlusion was determined by using standard cerebral angiography after treatment and either standard cerebral angiography or magnetic resonance angiography at follow-up examinations. Multiple angiographic projections were used in evaluating the percentage of occlusion. Adverse events were evaluated according to how they related to the GDC device, to the treatment, or to the disease. The severity of the event, the treatment given to the patient for that event, and the outcome of the event were also recorded. Deaths were recorded as being acutely device related or due to rebleeding or bleeding of treated lesions, other cerebrovascular events, or noncerebrovascular causes.
Twenty-seven patients withdrew from the study; eight of these underwent subsequent aneurysm clipping and two had other nonclipping surgical treatment (at least three of these patients died). Patients who died, those in whom no coils were placed, and those who underwent alternative procedures or an additional GDC treatment less than 6 months before reporting were not considered eligible for follow-up evaluation. Follow-up evaluation consisted of angiography and clinical evaluation based on Glasgow Outcome Scale (GOS) scores. [12, 13] Follow-up angiography was performed at 6 months (if clinically indicated, this was performed sooner or later than the usual 6 months) in 49 of the 83 patients with ruptured aneurysms and in 48 of the 67 patients with unruptured aneurysms. Glasgow Outcome Scale scores were obtained in 61 patients with ruptured aneurysms and 49 patients with unruptured aneurysms. The mean follow-up time was 13.7 months (range 0-43 months) for patients with ruptured aneurysms and 9.8 months (range 0-40 months) for patients with unruptured aneurysms.
RESULTS
No coils were placed in nine of the 159 enrolled patients (intent-to-treat failures). Of the 150 patients whose basilar tip aneurysms were treated with GDCs, treatment was considered clinically complete after one GDC procedure in 107 patients (71%). The remaining 43 patients (29%) underwent two or more GDC procedures. At least 90% posttreatment (acute) occlusion was achieved in 75% of the GDC-treated basilar tip aneurysms (75% for ruptured and 76% for unruptured). Based on the last reported follow-up angiograms (97 patients; 49 with ruptured and 48 with unruptured aneurysms) the degree of occlusion remained stable--greater than 90% occlusion in 79% of the aneurysms (78% ruptured and 81% unruptured). The average number of coils placed in a patient was seven (range 1-42), with increasing numbers of coils placed in larger basilar tip aneurysms. Coil stretching or migration occurred in four patients (3%), and errant coil placement occurred in three patients (2%).
Seventy-two (48%) of the 150 GDC-treated patients exhibited no periprocedural (defined as < 1 day posttreatment) or postprocedural adverse events. One adverse event occurred in 41 patients (27%) and more than one in 37 patients (25%). A record of the number and types of adverse events is shown in Table 2 , with cerebral embolism (23%) and vasospasm (8%) being the most common. Excluding the 19 periprocedural cerebral embolic events (13%), six of 10 cerebral emboli in the unruptured aneurysm group caused residual deficit (9% of the 67 treated patients who had unruptured aneurysms); four of five in the ruptured aneurysm group resulted in persistent deficit (5% of the 83 treated patients with ruptured aneurysms).
Only one patient with an unruptured aneurysm experienced vasospasm and this was periprocedural and transient. Three patients with ruptured aneurysms experienced periprocedural vasospasm: one patient died after receiving medical management and no angioplasty, one had an unknown outcome after receiving medical management, and one experienced resolution of vasospasm after receiving medical treatment. In the remaining eight patients with ruptured aneurysms who experienced postprocedural vasospasm, clinical outcomes included resolution of vasospasm after angioplasty in four patients; residual deficit after medical management and no angioplasty in two patients; death following angioplasty in one patient; and unknown outcome following medical management in one patient.
Two patients with ruptured basilar tip aneurysms suffered rebleeding after GDC treatment: one at 31 to 90 days (giant aneurysm) and the other at 91 to 365 days (aneurysm < 10 mm in diameter). Two patients with unruptured aneurysms suffered bleeding after GDC treatment: one at 31 to 90 days (symptomatic giant aneurysm) and the other at 91 to 365 days (aneurysm 11-25 mm in diameter). Rebleeding and bleeding rates for ruptured and unruptured aneurysms following GDC embolization in patients who completed follow-up evaluation are shown in Table 3 .
The frequency of signs and symptoms in patients before and after GDC treatment of their inoperable basilar tip aneurysms are shown in Table 4 . The patients' follow-up GOS clinical evaluations are summarized in Table 5 . Approximately 70% of all patients with treated ruptured or unruptured basilar tip aneurysms had a GOS score of 1.
There were four periprocedural deaths (2.7%); all occurred in patients with ruptured aneurysms. Based on the 110 patients with completed follow-up review, the overall posttreatment mortality rate was conservatively estimated to be up to 18% (20 
. Three (33%) of the nine patients with symptomatic unruptured giant basilar tip aneurysms treated with the GDC technique died. Eight of the 14 patients in the treated ruptured group who died did so within 2 weeks, compared with none of the six patients with treated unruptured aneurysms. The times of death for patients with both ruptured and unruptured aneurysms are shown in Table 6 .
Three deaths (3%) were caused by bleeding from an unruptured aneurysm (one patient) or rebleeding from a ruptured aneurysm (two patients); three (75%) of the four patients who suffered bleeding or rebleeding died. Fifty percent (seven of 14) of all deaths in patients with ruptured aneurysms occurred within 2 weeks in those patients who were treated "early" (within 14 days of ictus) ( Table 6 ). Half (three of six) of the deaths in patients with treated unruptured basilar tip aneurysms occurred in patients with giant aneurysms (> 25 mm) and half in patients with nongiant but symptomatic aneurysms; almost all deaths (five of six) in the unruptured aneurysm group occurred longer than 30 days after endovascular treatment (Table 6 ). In cases of ruptured aneurysms, chances of mortality increased with a higher Hunt and Hess grade (Table 7) .
DISCUSSION
From 20 to 65% of patients with aneurysms are relegated to conservative medical management because these patients are not surgical candidates. [30] For those who have a ruptured aneurysm that is treated conservatively, approximately 60% will die and 25 to 40% of those who survive the initial subarachnoid hemorrhage will develop significant levels of morbidity by 6 months. [15, 16, 23 ,29] Nishioka, et al., [22] reported a cumulative 37% risk of rebleeding at 4 weeks for those with a ruptured aneurysm. The estimated overall mortality rate from second hemorrhages in conservatively managed patients ranges from 34 to 42%. [19, 22] The goal of the FDA multicenter GDC clinical trial was to "provide treatment for certain intracranial aneurysms that because of their morphology, location, or the patient's general medical condition are considered by the treating neurosurgical team to be either at very high risk for management by traditional operative techniques or are inoperable." [1] These goals were established in an attempt to decrease the high morbidity and mortality rates of those patients with ruptured or symptomatic unruptured aneurysms relegated to conservative medical management for whatever reason. Use of the GDC technique in the treatment of basilar tip aneurysms is particularly appealing because this type of aneurysm, especially if large, can pose technical difficulties for the surgeon and, not surprisingly, these patients tend to fare even worse than those who have been surgically treated for other types of aneurysms. Indeed, Heros [9] states the possibility that this technique may become a competitive alternative to surgery for large aneurysms at the basilar tip "where surgical results in the hands of most neurosurgeons leave much to be desired."
Patients were selected for endovascular therapy only after the referring neurosurgeons excluded them as surgical candidates. The criteria were subjective inasmuch as neurosurgeons' clinical and operative judgments differ from institution to institution. However, a review of the list of participating centers (Appendix) shows that many of them are not only major centers for GDC embolization but are also leading academic centers of neurological surgery. This suggests that expert neurosurgical opinion was rendered prior to patient referral for GDC embolization. The overwhelming reason for GDC embolization referral was an anticipated surgical or technical problem in the clipping of the basilar tip aneurysm (70%).
The results we present are pooled data obtained from 21 centers in the United States, which represent the experience of at least as many endovascular interventionalists. As with any new technique, there is a learning curve and some neurointerventionalists are more skilled than others and have performed substantially more procedures. It has taken decades to perfect the microsurgical technique, [3] and, similarly, the endovascular technique will improve with time. For example, Moret and associates [20] recently published results they achieved with a modified GDC technique that allowed GDC embolization in 52 of 56 wide-necked or badly shaped intracranial aneurysms. As experience grows using the GDC, technical advances such as this may diminish the importance of aneurysm neck size and shape in achieving initial complete aneurysm packing. Accordingly, we believe that these current results should be viewed as conservative figures that should be, and are being, improved as individual centers report their experiences. [18] Indeed, as expected, more recent published reports document improved technical successes and much lower patient morbidity and mortality rates. [17, 21, 28] It should be noted that there are many limitations in the data in this study. At the time that the investigational device exemption was approved by the FDA and the multicenter investigational study was started, the manufacturer of the GDC and its consultants could not have foreseen the impact of the device on the treatment of inoperable aneurysms nor could they predict the importance of aneurysm configuration and neck size, coil compaction, and recanalization risk. It was only during and because of the 4-year investigational trial that the importance of such factors became apparent, not only for determining the technical success of the GDC but also for assessing its efficacy in preventing rebleeding. Unfortunately, important data such as aneurysm neck size and geometry were not consistently recorded at the time of treatment and, therefore, could not be analyzed in a meaningful manner.
For similar reasons, it was not possible to determine the percentages and degrees of recanalization nor was it possible to ascertain the percentages and degrees of further thrombosis. Additional treatments performed because of recanalization were not recorded. No correlation was made between the percentages of occlusion (subjectively reported at best) and recanalization and the aneurysm's size, shape, or neck. As experience has shown, aneurysms with wide necks are difficult to treat with clipping or coiling [4, 7, 8, 18] and larger aneurysms are likely to require retreatment as a result of further compaction of coils over time. Incomplete data are present to assess the protective nature of "acute" coiling: within 3 days is a better window than within 2 weeks. [5] A mean follow-up period of 10 to 13 months is relatively short; it remains to be proven whether the GDCs protect against rebleeding and initial hemorrhage for ruptured and unruptured aneurysms, respectively, once and if coil compaction and recanalization (analogous to the risk of a partially clipped aneurysm) occur.
Regardless, some of the results in the 150 patients (110 with follow-up review) with GDC-treated basilar tip aneurysms are promising when we compare the morbidity and mortality rates with those of conservative management. Estimates of the prognoses for individuals with surgically untreated ruptured intracranial aneurysms are based on limited data. The best information is probably derived from Pakarinen's series. [25] In an 8-year study of the entire population of Helsinki, 589 cases of subarachnoid hemorrhage were identified. Only 91 of these patients underwent surgery, with 70% of the operations performed at least 1 month after the initial hemorrhage. Mortality rates of 32%, 43%, 56%, and 60% were reported posthemorrhage at 1 day, 1 week, 1 month, and 6 months, respectively. Heros [10] confirms these dismal outcomes in a recent literature review.
In an unmatched comparison, our conservative estimates of up to a 23% mortality rate at longer than 6 months (7% periprocedural) for patients who have undergone treatment of ruptured basilar tip aneurysms and the more optimistic number of 17%, assuming all patients without follow up are alive, are encouraging. Recent reports from experienced centers of GDC embolization of basilar tip aneurysms in a smaller number of patients have provided mortality rates of 0 to 5%. [18, 21] Similarly, the rebleeding rate for ruptured basilar tip aneurysms treated with the GDCs is conservatively estimated up to 3.3% (0-3% in recent series). [18, 21] Moreover, clinical outcomes after treatment with GDCs for both ruptured and unruptured aneurysm groups are encouraging, with 70% of patients having a GOS score of 1. On the other hand, patients with Hunt and Hess Grade V did poorly regardless of the technical success of the GDC implantation, because most of these patients died as a result of sequelae of the initial bleeding.
The role of endovascular therapy in patients with unruptured basilar tip aneurysms is unclear. Most of the patients with unruptured basilar tip aneurysms in this study were symptomatic and/or harbored giant aneurysms. The overall mortality rate for this group was up to 12% (0% periprocedural) and the bleeding rate was up to 4.1%. Three (33%) of the patients with symptomatic giant aneurysms in this group died despite GDC treatment. These percentages may be too high to warrant routine endovascular therapy for symptomatic and giant basilar tip aneurysms in high-risk patients, but, again, the numbers and percentages from this study are conservative and newer studies will most likely find a more favorable risk-benefit profile for this procedure in this setting.
In addition to the 2.7% periprocedural death risk, the 5% (in patients with ruptured aneurysms) and 9% (in patients with unruptured aneurysms) permanent stroke morbidity rates and the two deaths attributable to vasospasm highlight the potential dangers of this procedure. Therefore, despite the simple concept of detachable coil embolization and the ease with which some cases are treated, it is mandatory that only appropriately trained specialists perform GDC embolization of aneurysms, particularly those of the basilar tip.
CONCLUSIONS
Based on the results of the FDA clinical trial, GDC embolization of ruptured basilar tip aneurysms not amenable to surgical clipping appears to decrease morbidity and mortality rates compared with the available information on the natural history of ruptured aneurysms treated conservatively. Patients with ruptured basilar tip aneurysms who are not surgical candidates should be offered GDC embolization as a treatment option. The role of endovascular therapy in the treatment of symptomatic or giant unruptured basilar tip aneurysms in patients who cannot be surgically treated is unclear. As experience is gained and longer follow-up studies are conducted, it is likely that the morbidity and mortality rates associated with this procedure will decrease further than those reported in this study for both ruptured and unruptured basilar tip aneurysms. A multicenter randomized controlled prospective study is warranted.
